TY - JOUR
T1 - Human papillomavirus vaccination coverage among young, gay, bisexual, and other men who have sex with men and transgender women — 3 U.S. cities, 2016–2018
AU - Amiling, Raiza
AU - Winer, Rachel L.
AU - Newcomb, Michael E.
AU - Gorbach, Pamina M.
AU - Lin, John
AU - Crosby, Richard A.
AU - Mustanski, Brian
AU - Markowitz, Lauri E.
AU - Meites, Elissa
N1 - Publisher Copyright:
© This work was authored as part of the Contributor’s official duties as an Employee of the United States Government and is therefore a work of the United States Government. In accordance with 17 USC. 105, no copyright protection is available for such works under US Law.
PY - 2021
Y1 - 2021
N2 - Gay, bisexual, and other men who have sex with men (MSM) and transgender women are disproportionately affected by human papillomavirus (HPV). HPV vaccination is routinely recommended for U.S. adolescents at age 11–12 years, with catch-up vaccination through age 26 years. We assessed HPV vaccination coverage and associated factors among young MSM and transgender women. The Vaccine Impact in Men study enrolled MSM aged 18–26 years from clinics in Seattle, Chicago, and Los Angeles, during February 2016–September 2018. Participants self-reported socio-demographic information and HPV vaccination status. Among 1416 participants, 673 (47.5%) reported ≥1 HPV vaccine dose. Among vaccinated participants, median age at first dose was 19 years and median age at first sex was 17 years; 493 (73.3%) reported that their age at first dose was older than their age at first sex. There were significant differences in HPV vaccination coverage by city (range 33%–62%), age, race/ethnicity, and gender identity. Coverage was highest in Seattle, where younger age was the only factor associated with vaccination. Differences in coverage by city may be due to variation in vaccination practices or enrollment at study sites. Increasing both routine and catch-up vaccination will improve coverage among MSM and transgender women.
AB - Gay, bisexual, and other men who have sex with men (MSM) and transgender women are disproportionately affected by human papillomavirus (HPV). HPV vaccination is routinely recommended for U.S. adolescents at age 11–12 years, with catch-up vaccination through age 26 years. We assessed HPV vaccination coverage and associated factors among young MSM and transgender women. The Vaccine Impact in Men study enrolled MSM aged 18–26 years from clinics in Seattle, Chicago, and Los Angeles, during February 2016–September 2018. Participants self-reported socio-demographic information and HPV vaccination status. Among 1416 participants, 673 (47.5%) reported ≥1 HPV vaccine dose. Among vaccinated participants, median age at first dose was 19 years and median age at first sex was 17 years; 493 (73.3%) reported that their age at first dose was older than their age at first sex. There were significant differences in HPV vaccination coverage by city (range 33%–62%), age, race/ethnicity, and gender identity. Coverage was highest in Seattle, where younger age was the only factor associated with vaccination. Differences in coverage by city may be due to variation in vaccination practices or enrollment at study sites. Increasing both routine and catch-up vaccination will improve coverage among MSM and transgender women.
KW - Vaccination coverage
KW - papillomavirus vaccines
KW - sexual and gender minorities
KW - vaccination
KW - young adult
UR - http://www.scopus.com/inward/record.url?scp=85125548962&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85125548962&partnerID=8YFLogxK
U2 - 10.1080/21645515.2021.2005436
DO - 10.1080/21645515.2021.2005436
M3 - Article
C2 - 35213950
AN - SCOPUS:85125548962
SN - 2164-5515
VL - 17
SP - 5407
EP - 5412
JO - Human Vaccines and Immunotherapeutics
JF - Human Vaccines and Immunotherapeutics
IS - 12
ER -
